Takeda Reports Successful Phase 3 Trial for Psoriasis Drug Zasocitinib

Takeda has announced positive outcomes from its Phase 3 LATITUDE Atlas study for zasocitinib, a new oral treatment for moderate-to-severe plaque psoriasis. The drug demonstrated superior efficacy compared to deucravacitinib, with a significantly higher percentage of patients achieving complete skin clearance. The safety profile remained consistent with prior research, indicating no new concerns.